MX2025014306A - Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona - Google Patents
Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-onaInfo
- Publication number
- MX2025014306A MX2025014306A MX2025014306A MX2025014306A MX2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A MX 2025014306 A MX2025014306 A MX 2025014306A
- Authority
- MX
- Mexico
- Prior art keywords
- synt
- novel
- synthesis
- variety
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832614P | 2019-04-11 | 2019-04-11 | |
| PCT/US2020/027655 WO2020210613A1 (en) | 2019-04-11 | 2020-04-10 | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025014306A true MX2025014306A (es) | 2026-01-07 |
Family
ID=70457148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025014306A MX2025014306A (es) | 2019-04-11 | 2020-04-10 | Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona |
| MX2021012286A MX2021012286A (es) | 2019-04-11 | 2020-04-10 | Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012286A MX2021012286A (es) | 2019-04-11 | 2020-04-10 | Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona. |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11788071B2 (en) | 2020-04-10 | 2023-10-17 | Codexis, Inc. | Engineered transaminase polypeptides |
| EP4225757A1 (en) * | 2020-10-12 | 2023-08-16 | Bristol-Myers Squibb Company | A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013033777A2 (pt) * | 2011-03-15 | 2016-09-13 | Abbvie Inc | moduladores de receptor de hormônio nuclear |
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (cg-RX-API-DMAC7.html) * | 2014-10-01 | 2018-10-20 | ||
| CN105294496A (zh) | 2015-09-28 | 2016-02-03 | 中山大学 | 一种西酞普兰中间体的制备方法 |
| CN110062757B (zh) | 2017-01-18 | 2022-03-04 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| CN113677682B (zh) | 2019-04-16 | 2023-05-30 | 华润生物医药有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| WO2021013209A1 (zh) | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| CA3179679A1 (en) | 2020-04-10 | 2021-10-14 | Codexis, Inc. | Carboxyesterase polypeptides for kinetic resolution |
-
2020
- 2020-04-10 EP EP23169596.6A patent/EP4234555A3/en active Pending
- 2020-04-10 CN CN202080041935.8A patent/CN114375290B/zh active Active
- 2020-04-10 CA CA3132365A patent/CA3132365A1/en active Pending
- 2020-04-10 ES ES20721374T patent/ES2969253T3/es active Active
- 2020-04-10 JP JP2021559890A patent/JP7631218B2/ja active Active
- 2020-04-10 EA EA202192807A patent/EA202192807A1/ru unknown
- 2020-04-10 BR BR112021020368A patent/BR112021020368A2/pt unknown
- 2020-04-10 IL IL287102A patent/IL287102B2/en unknown
- 2020-04-10 MX MX2025014306A patent/MX2025014306A/es unknown
- 2020-04-10 MX MX2021012286A patent/MX2021012286A/es unknown
- 2020-04-10 TW TW109112263A patent/TWI880924B/zh active
- 2020-04-10 KR KR1020267004972A patent/KR20260047658A/ko active Pending
- 2020-04-10 AU AU2020272973A patent/AU2020272973B2/en active Active
- 2020-04-10 WO PCT/US2020/027655 patent/WO2020210613A1/en not_active Ceased
- 2020-04-10 KR KR1020217036807A patent/KR102929951B1/ko active Active
- 2020-04-10 SG SG11202111132WA patent/SG11202111132WA/en unknown
- 2020-04-10 CN CN202411615118.5A patent/CN119775276A/zh active Pending
- 2020-04-10 US US17/602,059 patent/US12378246B2/en active Active
- 2020-04-10 EP EP20721374.5A patent/EP3953334B1/en active Active
- 2020-04-13 AR ARP200101024A patent/AR118649A1/es unknown
-
2025
- 2025-02-05 JP JP2025017468A patent/JP7885383B2/ja active Active
- 2025-06-18 US US19/242,506 patent/US20260092066A1/en active Pending
-
2026
- 2026-02-25 AU AU2026201396A patent/AU2026201396A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CO2021016967A2 (es) | Nuevos inhibidores de egfr | |
| BR112019003637A2 (pt) | um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino | |
| CL2019002792A1 (es) | Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo. | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| CL2022001492A1 (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| MX2019011758A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| CL2017003021A1 (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| CO2021011906A2 (es) | Anticuerpos claudina 6 y usos de los mismos | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| CR20160419A (es) | Nuevos compuestos biciclicos | |
| BR112017018276A2 (pt) | ?composição que compreende peptidase e biotensoativo e seu uso? | |
| MX2019004740A (es) | Composicion bucal de fases multiples para el cuidado bucal. | |
| MX2021003180A (es) | Métodos y kits para preparar sangre entera con inactivación de patógenos. | |
| NI202000087A (es) | Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
| MX2019011730A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| CY1125297T1 (el) | Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια | |
| MX2019010643A (es) | Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2). | |
| CO2022006965A2 (es) | Inhibidores de egfr | |
| MX390725B (es) | Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado. | |
| MX2019001053A (es) | Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados. | |
| MX2020004414A (es) | Compuestos y uso de los mismos en la expansion de celulas madre y/o celulas progenitoras. | |
| CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| CO2022002392A2 (es) | Síntesis de un inhibidor de calicreína plasmática a escala de proceso | |
| CL2024000248A1 (es) | Composiciones y métodos para anticuerpos anti-pacap |